Harvard John A. Paulson School of Engineering and Applied Sciences

Marissa Renardy, PhD, of Applied BioMath, Receives ISoP Emerging Scientist Award

Retrieved on: 
Friday, October 20, 2023
Harvard John A. Paulson School of Engineering and Applied Sciences, Mathematical and theoretical biology, OH, BS, MD, Doctor of Philosophy, Research, R, Statistics, COVID-19, Doctor of Pharmacy, Ohio State University, Utta Isop, University, Tuberculosis, Immunology, MS, Pharmaceutical industry, Microbiology, Mathematics, Virginia Tech

CONCORD, Mass., Oct. 20, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced Marissa Renardy, PhD, Principal Scientist at Applied BioMath received ISoP's Emerging Scientist Award.

Key Points: 
  • CONCORD, Mass., Oct. 20, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced Marissa Renardy, PhD, Principal Scientist at Applied BioMath received ISoP's Emerging Scientist Award.
  • Dr. Renardy will be recognized at the ACoP14 opening session and ISoP award's ceremony on Sunday, November 5, 2023.
  • The ISoP Emerging Scientist Award recognizes early-career scientists who are within five years of earning their MS, PharmD, PhD, or MD degree, and have made extraordinary impact in the fields of pharmacometrics, applied statistics, systems-based modeling and simulation, or a related scientific area.
  • "This is a very well-deserved recognition for Dr. Renardy," said John Burke, PhD, Co-founder, President and CEO of Applied BioMath.

Applied BioMath, LLC Announces Participation at AAPS 2023 PharmSci 360

Retrieved on: 
Thursday, October 19, 2023
Drug development, Science, Patient, Harvard John A. Paulson School of Engineering and Applied Sciences, Mathematical and theoretical biology, CSO, Bi-specific T-cell engager, Simulation, Doctor of Philosophy, AAPS, R, National Center for Advancing Translational Sciences, Messenger, UGT1A1, Biomarker, Translation, Crigler–Najjar syndrome, Pharmaceutical industry, Medical imaging, Management, Medical device

CONCORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at AAPS 2023 PharmSci 360 occurring October 22-25, 2023 in Orlando, FL.

Key Points: 
  • CONCORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at AAPS 2023 PharmSci 360 occurring October 22-25, 2023 in Orlando, FL.
  • Applied BioMath will participate in multiple presentations during the conference.
  • Joshua Apgar, PhD, Co-founder and CSO at Applied BioMath will give a Speaker Spotlight presentation entitled, "Evolving Clinical Pharmacology and Translational PK/PD Approaches for New Modalities" on Tuesday, October 24th from 9:30-10:30am.
  • To learn more about Applied BioMath, visit www.appliedbiomath.com .

Citadel Securities and Google Cloud Announce High-Performance Computing Study with Harvard University to Advance Heart Disease Research

Retrieved on: 
Wednesday, August 16, 2023
Citadel, Cloud, Addendum (research platform), ABF, Research, Harvard University, Google Cloud Platform, ABF The Soldiers' Charity, ETH Zurich, Harvard John A. Paulson School of Engineering and Applied Sciences, Artery, Medicine, Citadel Securities, Cloud computing, Running, Patient, HPC, Google Cloud, Applied science, Gordon Bell, LAMMPS, SEAS, Medical device, Video game, Engineering

MIAMI and SUNNYVALE, Calif. and CAMBRIDGE, Mass., Aug. 16, 2023 /PRNewswire/ -- Citadel Securities and Google Cloud today announced joint sponsorship of a cutting-edge medical research program at Harvard University demonstrating the validity of a novel, minimally invasive approach to unclogging arteries via a large-scale simulation powered by the public cloud. By leveraging high performance computing (HPC) running on cloud infrastructure, Harvard researchers will be able to solve some of the world's most complex calculations and advance heart disease research.

Key Points: 
  • By leveraging high performance computing (HPC) running on cloud infrastructure, Harvard researchers will be able to solve some of the world's most complex calculations and advance heart disease research.
  • Citadel Securities and Google Cloud are jointly funding and bringing top technical talent and technology together to demonstrate the power of scaled complex simulations for medical research.
  • "As a global team of technicians, statisticians, and quantitative problem solvers, Citadel Securities is uniquely positioned to support Prof. Koumoutsakos' visionary research," said Costas Bekas, Research Platform head at Citadel Securities.
  • Harvard's Office of Technology Development and SEAS worked in close coordination with Citadel Securities and Google Cloud to establish the joint sponsored research agreement.

NTT Research and NCVC to Form Bio Digital Twin Center

Retrieved on: 
Thursday, June 8, 2023
Technology, Other Technology, Health Technology, Cardiology, Software, Other Health, Biotechnology, Hardware, Health, Data Management, Heart, Medicine, Human, Nippon Telegraph and Telephone, Pharmacotherapy, CV, Myocardial infarction, NCVC, Harvard University, NTTR, Institute of technology, Digital twin, Kyushu University, Harvard John A. Paulson School of Engineering and Applied Sciences, Research, Hemodynamics, Organization, Innovation Center station, Hospital, Applied science, Constraint, MEI, Mathematics, NTT, Nigeria national cerebral palsy football team, Technical University of Munich, Pharmaceutical industry, Medical device, Engineering

NTT Research, Inc. , (NTTR) a division of NTT (TYO:9432), and the National Cerebral and Cardiovascular Center (NCVC) today announced an agreement to jointly launch a Bio Digital Twin Center in Suita, Japan.

Key Points: 
  • NTT Research, Inc. , (NTTR) a division of NTT (TYO:9432), and the National Cerebral and Cardiovascular Center (NCVC) today announced an agreement to jointly launch a Bio Digital Twin Center in Suita, Japan.
  • This initiative extends and expands the scope of a joint agreement on cardiovascular bio digital twin (CV BioDT) research between the two organizations reached in 2020.
  • Scientists at the NTTR-NCVC Bio Digital Twin Center intend to create applications by integrating mathematical models, co-developed by the MEI Lab and NCVC, onto the CV BioDT platform advanced by the MEI Lab.
  • Kazunori Uemura and Keita Saku (M.D., Ph.D.s) will lead the NTTR-NCVC Bio Digital Twin Center, respectively, as laboratory chief and acting director.

BASF celebrates 10 years of its Northeast Research Alliance

Retrieved on: 
Thursday, May 25, 2023
Plastic, Partnership, Circularity, University, Harvard University, AFL–CIO, National Science Foundation, Finger, Microplastics, Harvard John A. Paulson School of Engineering and Applied Sciences, Research, Recycling, Primary energy, Pulse, Stanley Black & Decker, Chemistry, Student, Climate change, University of Massachusetts Amherst College of Engineering, Iran National Science Foundation, Interdisciplinarity, Applied science, Catalysis, BASF, SE, BASF SE, Faculty, Massachusetts Institute of Technology, Ecosystem, Deep Decarbonization Pathways Project, NORA, Environment, Synthetic biology, Information technology, Management, University of Massachusetts, Engineering, MIT

Since its inception, NORA has evolved to stay competitive and drive innovation in the Massachusetts ecosystem. It expanded from a single university model with Harvard in 2008 to include MIT and the University of Massachusetts Amherst in 2013. NORA continued to expand in 2017 through BASF’s partnership with Greentown Labs -- the largest climatetech startup incubator in North America -- based in nearby Somerville, MA.

Key Points: 
  • At the conference, BASF announced its plans to expand the scope of NORA to include additional partners such as startups, accelerators, customers, research institutes, and other universities across North America to strengthen its innovation ecosystem.
  • NORA will stand for the North America Open Research Alliance moving forward.
  • “Harvard, MIT, UMass, and Greentown Labs will continue to play a leading role in the partnership between BASF and the broader innovation ecosystem in North America,” said Dr. Detlef Kratz, President of Group Research, BASF SE.
  • More than 100 postdocs and students and 47 faculty members have been involved in these projects, closely collaborating with key experts within BASF.

Harvard’s Wyss Institute and Collaborative Fund cofound research lab to fund technology to combat climate change

Retrieved on: 
Tuesday, May 23, 2023
Wyss Institute for Biologically Inspired Engineering, Plastic, Collaborative Fund, Bakalar, Food, North American Vascular Biology Organization, Dandelion Energy, Partnership, Education, Research, Harvard University, Innovation system, Innovation, Harvard John A. Paulson School of Engineering and Applied Sciences, Modern Meadow, Harvard Medical School, Commonwealth Fusion Systems, Nature, Climate change, Patent, Robotics, Head, Wyss Institute, Applied science, Water, Judah, Bioinspiration, Growth, Climate, Hospital, Textile, Laboratory, Synthetic biology, Renewable energy, Management, Engineering, Wyss

Collaborative Fund , a New York-based venture fund, is a leading source of capital and strategic support for entrepreneurs, businesses, and protocols pushing the world forward.

Key Points: 
  • Collaborative Fund , a New York-based venture fund, is a leading source of capital and strategic support for entrepreneurs, businesses, and protocols pushing the world forward.
  • As part of the alliance, Collaborative Fund will provide $15 million to create a Laboratory for Sustainable Materials Research and Innovation at the Wyss Institute to support research into transformational technology with strong commercial potential.
  • Collaborative Fund has over a decade of experience investing in climate technology and recently launched a dedicated $200M climate fund, Collab SOS , to fuel a more sustainable economy across materials, ingredients, energy, and supply chains.
  • When it comes to climate change, there’s no time to waste,” said Sophie Bakalar, partner at Collaborative Fund.

Berkeley Investments Moves Forward to Build New Innovation Cluster in Boston

Retrieved on: 
Monday, March 20, 2023
Professional Services, Residential Building & Real Estate, Commercial Building & Real Estate, Finance, Construction & Property, Urban Planning, Harvard Innovation Labs, Longwood Medical and Academic Area, Housing, Investment, Massachusetts Turnpike, LEED, Interstate 90, Logan International Airport, ART, Insteon, Multimedia, Research, Harvard University, CBT, I-90, Lincoln, City, Seaport District, Harvard Square, Mass, Triple accreditation, Applied science, Harvard Business School, Longwood Medical Area station, Project, Growth, Harvard John A. Paulson School of Engineering and Applied Sciences, R, Interstate Highway System, Commonwealth, LMA, SEAS, Birmingham Arts Lab, Tunnel, New Balance, Engineering, Greater Boston, Hudson Yards

The expanding Harvard presence in Allston is establishing a new cluster for innovation and research in Greater Boston and reinforcing the strong development link between two existing world-renowned medical research and life science clusters: the Longwood Medical Area (LMA) in Boston and the MIT/Kendall Square powerhouse in Cambridge.

Key Points: 
  • The expanding Harvard presence in Allston is establishing a new cluster for innovation and research in Greater Boston and reinforcing the strong development link between two existing world-renowned medical research and life science clusters: the Longwood Medical Area (LMA) in Boston and the MIT/Kendall Square powerhouse in Cambridge.
  • The two main commercial buildings will include 720,000 square feet of lab, R&D, and office space with exceptional branding opportunities along I-90 in one of the fastest-growing innovation districts in the Northeast.
  • Among the many sustainability features, the Project includes LEED Gold-certified buildings and a 100 percent electrical residential building, resulting in a 90 percent reduction in fossil fuel use.
  • Berkeley intends to break ground on 176 Lincoln in 2024 with a completion date in 2028.

NTT Research and Harvard Collaborate on Cardiovascular Bio Digital Twin

Retrieved on: 
Wednesday, November 16, 2022
Research, Technology, Health Technology, Cardiology, Biotechnology, University, Health, Science, Education, Artificial Intelligence, Cell, Sekisui Chemical, Physics, Disease, CV, DBG, Medicine, Technical University of Munich, Name, Institute of technology, Comenius University Faculty of Mathematics, Physics and Informatics, Research, IPS, Photonics, Cryptography, MEI, University, Neuroscience, Hope, PHI, Silicon, TUM, Electrode, Ireland national cerebral palsy football team, Munich School, Kyoto University, Nippon Telegraph and Telephone, Harvard John A. Paulson School of Engineering and Applied Sciences, Applied science, Bachelor of Engineering, MS, Physiology, Therapy, NCVC, CIS, NTT, SEAS, Information, Tissue, Harvard University, Organization, Electrophysiology, Heart, BS, Medical device, Mobile phone, Chemistry, Engineering, Informatics

NTT Research scientists will work with the Disease Biophysics Group (DBG) at SEAS to engineer a model of the human heart, elucidate fundamental laws of muscular pumps, and apply lessons learned to a cardiovascular (CV) bio digital twin model.

Key Points: 
  • NTT Research scientists will work with the Disease Biophysics Group (DBG) at SEAS to engineer a model of the human heart, elucidate fundamental laws of muscular pumps, and apply lessons learned to a cardiovascular (CV) bio digital twin model.
  • His groups long-term goal of engineering a living, functional heart maps well with our CV bio digital twin initiative.
  • I am honored to be joining the MEI Lab team at NTT Research while continuing complementary work at Harvard, Mr. Ishii said.
  • NTT Research is part of NTT, a global technology and business solutions provider with an annual R&D budget of $3.6 billion.

Unravel Biosciences licenses Wyss Institute platform technology from Harvard and Tufts University to decode, model, and treat complex diseases

Retrieved on: 
Tuesday, September 27, 2022
Nervous system, Health, Bioinspiration, Swimming, Seizure, Wyss Institute, Department, Brain, Sepsis, CRISPR, Hospital, TMA, Gene, Intellectual, Population, Applied science, Lists of diseases, Senior, Degenerative disease, Judah, Partnership, Industry, Research, Harvard University, Patient, Infection, Physiology, Intelligence, Proteome, Transcriptome, Technology, Rett syndrome, Biology, CEO, Â, CSO, Head, Diagnosis, Tufts University, Drug development, Wyss, Behavior, Wyss Institute for Biologically Inspired Engineering, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard Medical School, Lead, GLOBE, Vannevar Bush, Drug discovery, DARPA, Disease, Anatomy, Pharmaceutical industry, Dentistry, Engineering

Boston, MA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Today, Unravel Biosciences and the Wyss Institute for Biologically Inspired Engineering at Harvard University announced that Unravel has licensed a drug discovery platform technology from Harvard and Tufts University.

Key Points: 
  • Boston, MA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Today, Unravel Biosciences and the Wyss Institute for Biologically Inspired Engineering at Harvard University announced that Unravel has licensed a drug discovery platform technology from Harvard and Tufts University.
  • The company will use the technology, invented at the Wyss Institute, to decode and model complex diseases to accelerate the development of new and more effective therapies.
  • In contrast, we start with an individual patient and ask, What is different about this patient thats causing this disease?
  • Components of the CogniXense platform are being further developed at the Wyss Institute, and are being used in its Biostasis and CircaVent projects.

Science, Tech, and AI Leaders Convene to Launch Kempner Institute

Retrieved on: 
Friday, September 23, 2022
Computer science, Institute, Light, Faculty, Memory, Tears, Biohub, Brain, Yann, Success, Kempner, Schizophrenia, Chan Zuckerberg Initiative, Nature, Learning, Intelligence, Environment, Harvard University, Artificial intelligence, Technology, Student, Flood, Perception, Solution, Leadership, Dyslexia, Science, Provost, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard Medical School, Statistics, Research, Medicine, Multimedia, AI, Education, Sensation, Disease, Autism, CZI, Management, Engineering, Neuroscience

BOSTON, Sept. 23, 2022 /PRNewswire/ -- Today, leadership from the Chan Zuckerberg Initiative (CZI) and Harvard University celebrated the launch of the Kempner Institute for the Study of Natural and Artificial Intelligence at Harvard University with a symposium on Harvard's campus. Speakers included CZI Head of Science Stephen Quake, President of Harvard University Lawrence Bacow, Provost of Harvard University Alan Garber, and Kempner Institute co-directors Bernardo Sabatini and Sham Kakade. The event also included remarks and panels from industry leaders in science, technology, and artificial intelligence, including Bill Gates, Eric Schmidt, Andy Jassy, Daniel Huttenlocher, Sam Altman, Joelle Pineau, Sangeeta Bhatia, and Yann LeCun, among many others.

Key Points: 
  • Speakers included CZI Head of Science Stephen Quake, President of Harvard University Lawrence Bacow, Provost of Harvard University Alan Garber, and Kempner Institute co-directors Bernardo Sabatini and Sham Kakade.
  • The Kempner Institute will seek to better understand the basis of intelligence in natural and artificial systems.
  • The Kempner Institute will study AI systems, including artificial neural networks, to develop both principled theories and a practical understanding of how these systems operate and learn.
  • It will also focus on research topics such as learning and memory, perception and sensation, brain function, and metaplasticity.